Merck and Seattle Genetics have entered into two strategic oncology collaborations to commercialise Seattle Genetics’ antibody-drug conjugate (ADC) ladiratuzumab vedotin and small-molecule tyrosine kinase inhibitor (TKI) Tukysa (tucatinib).
Enrollment in the trial has been proceeding as planned and the company expects to reach its initial target of up to 30,000 participants next week. The proposed expansion
Dupixent, a fully-human monoclonal antibody, blocks the signalling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. The regulator has provided breakthrough therapy device designation based on data from
Terns recently completed a Phase 1 clinical study of TERN-201, which demonstrated that single and multiple oral administrations of TERN-201 were well tolerated with no significant safety findings
The company has reported positive pre-clinical results and confirmed the efficacy of the vaccine on the live SARS CoV-2 virus. ACvac1 is a prophylactic COVID-19 vaccine designed to
Deliveries would be starting by the end of 2020, subject to clinical success and regulatory authorization. The companies will now enter into contract negotiations with the European Commission.
The fine has been imposed on the companies for pushing the sales of Lucentis to treat age-related macular degeneration (AMD) over Avastin, which is available at low cost
Cheplapharm is a specialty pharmaceutical company headquartered in Germany with a 25-year history of successfully acquiring, integrating and growing pharmaceutical products. Takeda will receive an upfront payment of
Under the deal, Mylan will acquire Aspen’s portfolio that includes injectable anticoagulants marketed in Europe under the brand names and variations of the brand names such as Arixtra,
The term “orphan drugs” refers to pharmaceutical products developed for the prevention, diagnosis, and treatment of rare diseases or conditions. In the United States, an orphan disease is
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.